Literature DB >> 2527024

A prospective study of Alzheimer disease in Down syndrome.

F Lai1, R S Williams.   

Abstract

Ninety-six individuals with Down syndrome over age 35 years were evaluated and followed up for evidence of nontreatable dementia. Dementia was judged to be present when a functional decline occurred in areas such as orientation, memory, verbal and motor skills, and self-care abilities. Forty-nine patients with Down syndrome fit this criterion, with an average onset of dementia at 54.2 +/- 6.1 years. The prevalence of dementia in the institutionalized Down syndrome population of our study (n = 53) was 8% (2/25 patients) between 35 and 49 years, 55% (11/20 patients) between 50 and 59 years, and 75% (6/8 patients) of those over 60 years old. Of note, 41 (84%) demented individuals with Down syndrome developed seizures. Ten (20%) had parkinsonian features. Adequately treated hypothyroidism was present in 27 (59%) of 46 demented patients with Down syndrome tested. The average duration of dementia in the 23 patients who died was 4.6 +/- 3.2 years. Computed tomographic scans in 43 patients all showed brain tissue loss, most pronounced in the temporal lobes. Brains from 12 autopsied cases showed large numbers of plaques and tangles in the same locations as in persons with Alzheimer disease.

Entities:  

Mesh:

Year:  1989        PMID: 2527024     DOI: 10.1001/archneur.1989.00520440031017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  119 in total

Review 1.  Seizures and epilepsy in Alzheimer's disease.

Authors:  Daniel Friedman; Lawrence S Honig; Nikolaos Scarmeas
Journal:  CNS Neurosci Ther       Date:  2011-06-07       Impact factor: 5.243

2.  Selective loss of nigral neurons in Alzheimer's disease: a morphometric study.

Authors:  T Uchihara; H Kondo; K Kosaka; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Working memory in the aged Ts65Dn mouse, a model for Down syndrome.

Authors:  Katharine N Whitney; Galen R Wenger
Journal:  Behav Brain Res       Date:  2012-04-04       Impact factor: 3.332

4.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

Review 5.  Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

6.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

Review 7.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

8.  Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain.

Authors:  J Motte; R S Williams
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

9.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

10.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.